The Trump administration’s December 2025 executive order directing expedited rulemaking under the Controlled Substances Act has accelerated federal marijuana rescheduling from Schedule I to Schedule III, building on the prior HHS recommendation and Biden-era proposal. In late April 2026, the Department of Justice immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while terminating earlier proceedings and scheduling a new administrative hearing for June 29, 2026, to address broader reclassification. This hearing process, including public comment deadlines in May and potential final rulemaking, represents the primary near-term catalyst that could shift timelines. Traders are monitoring these procedural steps and any further executive or agency actions for signals on whether full rescheduling occurs by mid-year or extends into later 2026.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$758,577 Vol.
Mar 31, 2026
June 30
1%
December 31
24%
$758,577 Vol.
June 30
$337,166 Vol.
1%
December 31
$156,529 Vol.
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s December 2025 executive order directing expedited rulemaking under the Controlled Substances Act has accelerated federal marijuana rescheduling from Schedule I to Schedule III, building on the prior HHS recommendation and Biden-era proposal. In late April 2026, the Department of Justice immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while terminating earlier proceedings and scheduling a new administrative hearing for June 29, 2026, to address broader reclassification. This hearing process, including public comment deadlines in May and potential final rulemaking, represents the primary near-term catalyst that could shift timelines. Traders are monitoring these procedural steps and any further executive or agency actions for signals on whether full rescheduling occurs by mid-year or extends into later 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Feb 7, 2026, 5:04 PM ET
Volume
$758,577Tanggal Berakhir
Mar 31, 2026Pasar Dibuka
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s December 2025 executive order directing expedited rulemaking under the Controlled Substances Act has accelerated federal marijuana rescheduling from Schedule I to Schedule III, building on the prior HHS recommendation and Biden-era proposal. In late April 2026, the Department of Justice immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while terminating earlier proceedings and scheduling a new administrative hearing for June 29, 2026, to address broader reclassification. This hearing process, including public comment deadlines in May and potential final rulemaking, represents the primary near-term catalyst that could shift timelines. Traders are monitoring these procedural steps and any further executive or agency actions for signals on whether full rescheduling occurs by mid-year or extends into later 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$758,577Tanggal Berakhir
Mar 31, 2026Pasar Dibuka
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Trump administration’s December 2025 executive order directing expedited rulemaking under the Controlled Substances Act has accelerated federal marijuana rescheduling from Schedule I to Schedule III, building on the prior HHS recommendation and Biden-era proposal. In late April 2026, the Department of Justice immediately moved FDA-approved products and state-licensed medical marijuana into Schedule III while terminating earlier proceedings and scheduling a new administrative hearing for June 29, 2026, to address broader reclassification. This hearing process, including public comment deadlines in May and potential final rulemaking, represents the primary near-term catalyst that could shift timelines. Traders are monitoring these procedural steps and any further executive or agency actions for signals on whether full rescheduling occurs by mid-year or extends into later 2026.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan